1 Targeting the intracellular tyrosine kinase domain of HER2 with small-molecule tyrosine kinase inhibitors (TKIs) is a highly rational therapeutic approach that has been extremely successful in the ...

Emerging treatments like tyrosine kinase inhibitors (TKIs) offer promise by targeting complementary pathways in angiogenesis and providing sustained-release options to reduce injection frequency.

In this article, we address the role of tyrosine kinase inhibitors in tumor immunology by summarizing their effects on myeloid cells, such as antigen-presenting cells and regulatory cells ...

Protein kinase inhibitors can be subdivided according to the amino acid on a protein that they add the phosphate to (e.g serine, threonine or tyrosine) in order to inhibit phosphorylation of that ...

If you continue to have this issue please contact [email protected]. Tyrosine kinase inhibitors (TKIs) are emerging as a promising class of therapies for managing neovascular age ...

Treatment of chronic myeloid leukemia (CML) has changed drastically with the emergence of the Abl tyrosine kinase inhibitor (TKI), imatinib mesylate. However, primary and secondary resistance have ...

More information: A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised ...

and thus tyrosine kinase inhibitors, which reduce or eliminate the intensity of these signals, are under thorough investigation as anticancer agents. Compared to other chemotherapeutics tyrosine ...

Protein tyrosine kinases (PTK ... have been matched by the identification of new structural classes of kinase inhibitors with improved potency, specificity and efficacy. Subsequently, the majority ...

Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) and is effective in chronic lymphocytic leukemia (CLL). Resistance to irreversible kinase inhibitors and resistance ...